Altimmune (ALT) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$210.8 million.
- Altimmune's Enterprise Value fell 5120.86% to -$210.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$210.8 million, marking a year-over-year decrease of 5120.86%. This contributed to the annual value of -$131.9 million for FY2024, which is 3331.87% up from last year.
- As of Q3 2025, Altimmune's Enterprise Value stood at -$210.8 million, which was down 5120.86% from -$183.2 million recorded in Q2 2025.
- Over the past 5 years, Altimmune's Enterprise Value peaked at -$131.9 million during Q4 2024, and registered a low of -$226.5 million during Q1 2021.
- Moreover, its 5-year median value for Enterprise Value was -$183.2 million (2025), whereas its average is -$179.6 million.
- Per our database at Business Quant, Altimmune's Enterprise Value crashed by 58745.68% in 2021 and then soared by 3331.87% in 2024.
- Over the past 5 years, Altimmune's Enterprise Value (Quarter) stood at -$190.4 million in 2021, then rose by 2.87% to -$184.9 million in 2022, then decreased by 7.0% to -$197.9 million in 2023, then soared by 33.32% to -$131.9 million in 2024, then tumbled by 59.79% to -$210.8 million in 2025.
- Its Enterprise Value stands at -$210.8 million for Q3 2025, versus -$183.2 million for Q2 2025 and -$149.9 million for Q1 2025.